Hims & Hers Health is trading 4.77% up at €24.60, with no clear September 14, 2026 company announcement or explicit catalyst identified in reliable coverage.
- Reuters lists no same-day announcement or analyst action.
- JPMorgan began coverage on September 11 with a Neutral rating and a $32 target, but reporting does not directly link the note to today’s gain.
- Broader markets are moving lower, leaving the stock divergent from market sentiment.